GlaxoSmithKline: A Swine Flu Windfall?

British pharmaceutical giant GlaxoSmithKline (GSK) is set to reap billions as fear of the swine flu pandemic grows. The world's second-largest drug company has secured orders from 16 countries for 195 million doses of the vaccine it is developing against the H1N1 virus, which has killed more than 740 people worldwide.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.